Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20725708 | 0.87 | PIK3CA (0.37) | PIK3CAPIK3CDRXFP1PIK3R1MTOR | |
| SCHEMBL17053401 | 0.86 | PIK3CA (0.39) | PIK3CAPIK3CDRXFP1PIK3R1MTOR | |
| SCHEMBL16639095 | 0.82 | PIK3CA (0.37) | PIK3CAPIK3CDLMNASMN1; SMN2EPHB4 | |
| SCHEMBL17053424 | 0.82 | NOS3 (0.36) | PIK3CAPIK3R1MTOREPHB4 | |
| SCHEMBL17053410 | 0.77 | PIK3CA (0.52) | PIK3CAPIK3CDPIK3R1MTORSMN1; SMN2 | |
| SCHEMBL16639154 | 0.75 | PIK3CA (0.36) | PIK3CAPIK3CDPIK3R1MTOREPHB4 | |
| SCHEMBL16639078 | 0.75 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3R1MTOR | |
| SCHEMBL16639096 | 0.73 | PIK3CD (0.41) | PIK3CAPIK3CDPIK3R1MTORLMNA | |
| SCHEMBL17946922 | 0.71 | AURKA (0.45) | PIK3CAPIK3CD | |
| SCHEMBL1682836 | 0.71 | HTT (0.36) | EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2860181-B1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2019-02-13 | — | — | EP | disclosed |
| US-9499561-B2 | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-9499561-B2 | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | SHANGHAI YUNYI HEALTHCARE AND TECHNOLOGY CO., LTD. (CN) | 2015-09-03 | — | — | US | disclosed |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | SHANGHAI YUNYI HEALTHCARE AND TECHNOLOGY CO., LTD. (CN) | 2015-09-03 | — | — | US | disclosed |
| EP-2860181-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES THEREOF | Shanghai Yingli Science and Technology Co., Ltd (CN) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CD 2/4885RXFP1 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.